Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
10.0
5.6
Journals
IJMS
Special Issues
Canonical and Noncanonical Inflammasomes in Inflammation and Diseases
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Canonical and Noncanonical Inflammasomes in Inflammation and Diseases

A Special Issue of International Journal of Molecular Sciences (ISSN 1422-0067) belonging to the section "Molecular Immunology".

Deadline for manuscript submissions: 31 December 2026 | Viewed by 2759

Editor

Dr. Young-Su Yi

E-Mail Website
Guest Editor
Department of Life Sciences, Kyonggi University, Suwon 16227, Republic of Korea
Interests: inflammation; inflammatory/autoimmune diseases; noncanonical inflammasomes; macrophage; anti-inflammatory therapeutics; signaling transduction; immunology; molecular biology; biochemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The inflammasome is an intracellular protein complex that provides a molecular platform for inflammatory responses to a variety of the pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs). The inflammasome is classified into canonical and noncanonical inflammasomes, and has been demonstrated to play a crucial role in inflammation and diseases. However, the roles of both canonical and noncanonical inflammasomes, as well as how their dysregulation contributes to inflammatory responses and diseases, are still not well understood and require further investigation.

This Special Issue aims to investigate the regulatory roles of both canonical and noncanonical inflammasomes in inflammation and diseases and to provide insights into the development of new anti-inflammatory therapeutics by targeting inflammasomes.

Potential topics include but are not limited to

  1. the roles of canonical and noncanonical inflammasomes in inflammatory responses and human diseases,
  2. the underlying mechanisms,
  3. identifying and validating novel molecules interplaying with inflammasomes,
  4. evaluating anti-inflammatory effects by targeting inflammasomes, and
  5. developing potential inflammasome-targeted therapeutics.

Dr. Young-Su Yi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • canonical
  • noncanonical
  • inflammasome
  • inflammation
  • human diseases
  • anti-inflammatory therapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

23 pages, 1492 KB  
Review
Targeting the NLRP3 Inflammasome with Colchicine in COVID-19: Therapeutic Evidence and Future Implications for Influenza
by Vanyo Mitev
Int. J. Mol. Sci. 2026, 27(15), 6827; https://doi.org/10.3390/ijms27156827 - 30 Jul 2026
Cited by 1 | Viewed by 655
Abstract
Coronavirus disease 2019 (COVID-19) and influenza share key pathogenic mechanisms, including viral invasion, dysregulated innate immune activation, and the development of severe systemic complications. A central mediator of disease progression in both infections is the hyperactivation of the NLRP3 inflammasome, which drives excessive [...] Read more.
Coronavirus disease 2019 (COVID-19) and influenza share key pathogenic mechanisms, including viral invasion, dysregulated innate immune activation, and the development of severe systemic complications. A central mediator of disease progression in both infections is the hyperactivation of the NLRP3 inflammasome, which drives excessive production of pro-inflammatory cytokines, immunothrombosis, multiorgan injury, and increased mortality. Colchicine possesses a unique pharmacokinetic property of preferential accumulation within myeloid cells, where sufficiently high intracellular concentrations inhibit NLRP3 inflammasome activation. This mechanism provides a biological rationale for preventing the cytokine storm and its downstream consequences when colchicine is administered early during infection. Available pharmacokinetic, toxicological, and clinical evidence suggests that loading doses of colchicine up to approximately 0.05 mg/kg body weight can be administered safely in appropriately selected patients, provided that clinically significant drug–drug interactions and hepatic or renal impairment are carefully excluded. The widely accepted belief that total doses of 7–7.5 mg are inherently lethal appears to reflect historical cases complicated by drug interactions and/or hepatic or renal impairment, rather than toxicity attributable to colchicine dose alone. These observations support reconsideration of current guideline recommendations regarding colchicine dosing. In particular, cumulative doses below 0.1 mg/kg appear to be consistently safe, whereas doses between 0.1 and 0.2 mg/kg are associated with only a low risk of toxicity and rarely with severe intoxication. Reassessment of colchicine dosing strategies may therefore be warranted to optimize NLRP3 inflammasome inhibition and improve outcomes in patients with COVID-19 and influenza. Full article
(This article belongs to the Special Issue Canonical and Noncanonical Inflammasomes in Inflammation and Diseases)
►▼ Show Figures

Figure 1

18 pages, 1832 KB  
Review
Regulatory Roles of Noncanonical Inflammasomes in Diabetes Mellitus and Diabetes-Associated Complications
by Young-Su Yi
Int. J. Mol. Sci. 2025, 26(18), 8893; https://doi.org/10.3390/ijms26188893 - 12 Sep 2025
Cited by 3 | Viewed by 1171
Abstract
Inflammation is an innate immune system protecting the body from infection and injury. This process proceeds through two distinct stages: a priming phase, characterized by transcriptional activation, and a triggering phase, in which inflammasomes, cytosolic multiprotein complexes, are activated to initiate inflammatory signaling [...] Read more.
Inflammation is an innate immune system protecting the body from infection and injury. This process proceeds through two distinct stages: a priming phase, characterized by transcriptional activation, and a triggering phase, in which inflammasomes, cytosolic multiprotein complexes, are activated to initiate inflammatory signaling cascades. Canonical inflammasomes, the first to be identified, have been extensively implicated in the pathogenesis of diverse inflammatory disorders. In contrast, noncanonical inflammasomes have only recently been characterized, and their precise contributions to immune regulation and disease development remain incompletely defined. Diabetes mellitus (DM), simply diabetes, represents a heterogeneous group of metabolic disorders marked by chronic hyperglycemia and is associated with a broad spectrum of complications. The involvement of canonical inflammasomes in DM and its complications has been well demonstrated. More recently, however, accumulating evidence has uncovered crucial roles for noncanonical inflammasomes in the pathogenesis of DM and related complications This review comprehensively discusses current advances in understanding the regulatory functions of murine caspase-11 and human caspase-4/5 noncanonical inflammasomes in the pathogenesis of DM and diabetes-associated complications, highlighting their potential as novel therapeutic targets. Full article
(This article belongs to the Special Issue Canonical and Noncanonical Inflammasomes in Inflammation and Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop